The benefit of nivolumab/ipilimumab plus single-agent nivolumab for unresectable advanced melanoma with poor prognostic characteristics was comparable in all-comers and patients with brain metastases.
2023
Key Statistics for Melanoma Skin Cancer
Cancer of the skin is by far the most common of all cancers. Melanoma accounts for only about 1% of skin cancers but causes a large majority of skin cancer deaths.
PRT811 Showcases Early Signals of Efficacy in IDH-Mutant Glioma and Uveal Melanoma
Varun Monga, MBBS, discusses the mechanism of action of PRT811, key efficacy and safety findings from a phase 1 trial investigating the agent, and potential future directions with this agent in uveal melanoma and IDH-mutant high-grade glioma.
Treatments, Patient Characteristics Affect Uveal Melanoma Survival
A new study identified the elements that could determine the overall survival of patients with the metastatic eye tumor, uveal melanoma.